Catalyst Wire Dossier Catalyst Wire Dossier

Gocatamig

MK-6070 · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Gocatamig, covering 2026-04-13 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) [Phase 1, Phase 2]

See pricing